Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

A Transgenic Rat Model of Charcot-Marie-Tooth Disease


Nave,  Klaus-Armin
Neurogenetics, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Sereda, M., Griffiths, I., Pühlhofer, A., Stewart, H., Rossner, M. J., Zimmermann, F., et al. (1996). A Transgenic Rat Model of Charcot-Marie-Tooth Disease. Neuron, 16(5), 1049-1060. doi:10.1016/S0896-6273(00)80128-2.

Cite as: https://hdl.handle.net/21.11116/0000-000D-1F58-F
Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy in humans and has been associated with a partial duplication of chromosome 17 (CMT type 1A). We have generated a transgenic rat model of this disease and provide experimental evidence that CMT1A is caused by increased expression of the gene for peripheral myelin protein-22 (PMP22, gas-3). PMP22-transgenic rats develop gait abnormalities caused by a peripheral hypomyelination, Schwann cell hypertrophy (onion bulb formation), and muscle weakness. Reduced nerve conduction velocities closely resemble recordings in human patients with CMT1A. When bred to homozygosity, transgenic animals completely fail to elaborate myelin. We anticipate that the CMT rat model will facilitate the identification of a cellular disease mechanism and serve in the evaluation of potential treatment strategies.